tetano
Editor, Senior Moderator
Cell Mol Life Sci
. 2022 Feb 20;79(3):142.
doi: 10.1007/s00018-021-04096-y.
Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
Lijun Chen[SUP] 1 [/SUP], Jingjing Qu[SUP] 2 [/SUP], Farhin Shaheed Kalyani[SUP] 2 [/SUP], Qi Zhang[SUP] 1 [/SUP], Lingzhi Fan[SUP] 3 [/SUP], Yangxin Fang[SUP] 1 [/SUP], Yifei Li[SUP] 1 [/SUP], Charlie Xiang[SUP] 4 [/SUP]
Affiliations
Abstract
As a result of cross-species transmission in December 2019, the coronavirus disease 2019 (COVID-19) became a serious endangerment to human health and the causal agent of a global pandemic. Although the number of infected people has decreased due to effective management, novel methods to treat critical COVID-19 patients are still urgently required. This review describes the origins, pathogenesis, and clinical features of COVID-19 and the potential uses of mesenchymal stem cells (MSCs) in therapeutic treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients. MSCs have previously been shown to have positive effects in the treatment of lung diseases, such as acute lung injury, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, lung cancer, asthma, and chronic obstructive pulmonary disease. MSC mechanisms of action involve differentiation potentials, immune regulation, secretion of anti-inflammatory factors, migration and homing, anti-apoptotic properties, antiviral effects, and extracellular vesicles. Currently, 74 clinical trials are investigating the use of MSCs (predominately from the umbilical cord, bone marrow, and adipose tissue) to treat COVID-19. Although most of these trials are still in their early stages, the preliminary data are promising. However, long-term safety evaluations are still lacking, and large-scale and controlled trials are required for more conclusive judgments regarding MSC-based therapies. The main challenges and prospective directions for the use of MSCs in clinical applications are discussed herein. In summary, while the clinical use of MSCs to treat COVID-19 is still in the preliminary stages of investigation, promising results indicate that they could potentially be utilized in future treatments.
Keywords: Cellular therapy; Coronavirus disease 2019 (COVID-19); Mesenchymal stem cell; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2022 Feb 20;79(3):142.
doi: 10.1007/s00018-021-04096-y.
Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
Lijun Chen[SUP] 1 [/SUP], Jingjing Qu[SUP] 2 [/SUP], Farhin Shaheed Kalyani[SUP] 2 [/SUP], Qi Zhang[SUP] 1 [/SUP], Lingzhi Fan[SUP] 3 [/SUP], Yangxin Fang[SUP] 1 [/SUP], Yifei Li[SUP] 1 [/SUP], Charlie Xiang[SUP] 4 [/SUP]
Affiliations
- PMID: 35187617
- DOI: 10.1007/s00018-021-04096-y
Abstract
As a result of cross-species transmission in December 2019, the coronavirus disease 2019 (COVID-19) became a serious endangerment to human health and the causal agent of a global pandemic. Although the number of infected people has decreased due to effective management, novel methods to treat critical COVID-19 patients are still urgently required. This review describes the origins, pathogenesis, and clinical features of COVID-19 and the potential uses of mesenchymal stem cells (MSCs) in therapeutic treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients. MSCs have previously been shown to have positive effects in the treatment of lung diseases, such as acute lung injury, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, lung cancer, asthma, and chronic obstructive pulmonary disease. MSC mechanisms of action involve differentiation potentials, immune regulation, secretion of anti-inflammatory factors, migration and homing, anti-apoptotic properties, antiviral effects, and extracellular vesicles. Currently, 74 clinical trials are investigating the use of MSCs (predominately from the umbilical cord, bone marrow, and adipose tissue) to treat COVID-19. Although most of these trials are still in their early stages, the preliminary data are promising. However, long-term safety evaluations are still lacking, and large-scale and controlled trials are required for more conclusive judgments regarding MSC-based therapies. The main challenges and prospective directions for the use of MSCs in clinical applications are discussed herein. In summary, while the clinical use of MSCs to treat COVID-19 is still in the preliminary stages of investigation, promising results indicate that they could potentially be utilized in future treatments.
Keywords: Cellular therapy; Coronavirus disease 2019 (COVID-19); Mesenchymal stem cell; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).